Xilio Therapeutics, Inc.
NASDAQ:XLOBiotechnology
Healthcare
$7.51 +5.14%
+$0.45 today
- Market cap
- $53.05M
- Beta
- -0.09
- P/E (TTM)
- -48.1
- EPS (TTM)
- -$0.19
52W Low $6.47High $12.74
Volume 0.00M
Average 0.05M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$4.99M
FY 2025 · Annual
Investing Cash Flow
-$518,000.00
FY 2025 · Annual
Financing Cash Flow
$87.78M
FY 2025 · Annual
+200.6% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (75.8M) | (88.22M) | (76.4M) | (58.24M) | (35.04M) |
| Depreciation & Amortization | 1.5M | 1.85M | 1.9M | 1.64M | 1.54M |
| Deferred Income Tax | 222K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.96M | 8.42M | 7.38M | 6.43M | 6.94M |
| Change in Working Capital | (11.8M) | 2M | (1.66M) | 31.78M | 25.13M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (5M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.82M) | 485K | (2.06M) | 1.53M | 152K |
| Other Working Capital | (8.99M) | 1.52M | 405K | 30.26M | 29.97M |
| Other Non-Cash Items | 173K | 224K | 160K | 3K | (3.56M) |
| Operating Cash Flow | (80.75M) | (75.72M) | (68.62M) | (18.38M) | (4.99M) |
| Capital Expenditures | (1.1M) | (1.87M) | (486K) | (36K) | (518K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.1M) | (1.87M) | (486K) | (36K) | (518K) |
| Debt Repayment | (110K) | (85K) | (6.75M) | (3.38M) | 0 |
| Common Stock Issued | 116.36M | 16K | 202K | 6.83M | 87.78M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (467K) | 0 | 0 | 25.75M | 0 |
| Financing Cash Flow | 260.67M | (69K) | (6.55M) | 29.2M | 87.78M |
| Effect of Forex Changes | 0 | (9K) | (25K) | 0 | 0 |
| Net Change in Cash | 178.82M | (77.67M) | (75.68M) | 10.78M | 82.27M |
| Free Cash Flow | (81.85M) | (77.59M) | (69.11M) | (18.41M) | (5.51M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$35.0M
+ D&A$1.5M
+ Stock-Based Comp$6.9M
+ Deferred Tax$0
+ Working Capital$25.1M
- Other Non-Cash-$3.6M
= Operating Cash Flow-$5.0M
- Capex-$518.0K
= Free Cash Flow-$5.5M
Analysis
FY2025 free cash flow is -$5.5M. FCF conversion is 15.7% of net income. Operating cash flow was -$5.0M, with capex of -$518.0K. The largest bridge item is Working Capital at $25.1M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 12, 2026 | |
| S-8 | S-8 filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 |
Does XLO generate free cash flow?
Xilio Therapeutics, Inc. (XLO) generated -$5.51M of free cash flow in fiscal 2025.
How much operating cash flow does XLO produce?
Operating cash flow was -$4.99M, before capital expenditures of $518,000.00.
Continue the stock analysis
Jump to another research area for this company.